Granular cell tumor in axillary region: A rare entity

  • Authors:
    • Kamil Pohlodek
    • Peter Jáni
    • Iveta Mečiarová
  • View Affiliations

  • Published online on: February 7, 2018     https://doi.org/10.3892/mco.2018.1568
  • Pages: 579-581
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A granular cell tumor (GCT), is a rare soft tissue tumor which may occur throughout the body, usually in the head and neck, skin or subcutaneous tissues of the trunk and upper extremities, and female genital region. A total of 5‑8% of all cases of GCTs occur in the breast. GCT of the breast may mimic breast cancer both clinically and radiologically. GCTs are usually benign and solitary; however, approximately 2% occur as malignant tumors. Benign GCTs are treated with wide local excision and are associated with a good prognosis. The current case report presents findings in a patient with a benign form of GCT in a rare location, specifically in the axillary region.

Introduction

Castleman's disease (CD), first described by Castleman in 1954 (1), is commonly encountered in the chest and neck, but is less common in the abdomen and rare in the liver. Primary hepatic CD is very rare, with <20 cases reported in the literature to date (2). Furthermore, description of computed tomography (CT) and magnetic resonance imaging (MRI) characteristics of hepatic CD is rarely found in the radiological literature, particularly from diffusion-restricted on diffusion-weighted imaging (DWI), and CD may be misdiagnosed as a malignant lesion (3). Therefore, the radiological diagnosis of hepatic CD remains difficult. We herein describe a case of hepatic CD detected by CT and MRI, along with a review of the previous cases reported in the literature, with the aim to help improve our understanding and radiological diagnosis of hepatic CD.

Case report

An asymptomatic 70-year-old woman underwent a routine physical examination in a local hospital, during which a focal lesion was identified in the right lobe of the liver via ultrasound. The patient received no immediate treatment and was referred for further evaluation to the First Affiliated Hospital of Zhejiang Chinese Medical University (Hangzhou, China). The findings on physical examination and the results of the laboratory tests, including complete blood count and basic metabolic panels, were normal. Subsequently, the patient underwent CT (Somatom, Sensation 64; Siemens, Waltershausen, Germany) and MRI (3.0T Discovery 750; GE Healthcare, Chicago, IL, USA) scans of the abdomen for further evaluation and, finally, the focal lesion was surgically resected.

A non-enhanced abdominal CT was first conducted and revealed well-defined nodular hypoattenuation with punctate hyperattenuation (Fig. 1A, arrow) within a lesion in the eighth segment of the liver. On enhanced CT imaging, the lesion exhibited nodular enhancement (2.3×1.9 cm), and a strip-like enhanced area was found to extend from the nodule in the arterial phase 30 sec after injection of iodine contrast agent (Fig. 1B, arrows), with persistent enhancement in the portal venous phase 65 sec after injection of iodine contrast agent (Fig. 1C).

A follow-up MRI was performed 10 days later and revealed a well-defined nodule (2.6×2.0 cm) with an extended strip in the eighth segment of the liver on T2-weighted imaging. Punctate hypointensity was also observed in the center of the nodule (Fig. 2A, arrow). Both the nodule and the strip displayed hyperintensity on DWI (b=800 sec/mm2, Fig. 2B) with a low apparent diffusion coefficient (ADC) value (0.622×10−3 and 0.693×10−3 mm2/sec, respectively; Fig. 2C). Compared with non-enhanced T1-weighted MR images (Fig. 2D), post-contrast MRI revealed significant enhancement of the nodule and the strip in the arterial phase 30 sec after gadolinium injection (Fig. 2E, arrows), and persistent enhancement in the parenchymal phase 120 sec after gadolinium injection (Fig. 2F).

The lesion in the right liver was resected by surgical laparoscopy under general anesthesia. Postoperative pathological examination demonstrated that the pathological components of the nodular mass were lymphocytes and hyalinized vessels (Fig. 3A), with the strip-like area being composed mainly of lymphocytes (Fig. 3B).

Postoperative treatment of the patient was administration with Saimeijie (an atypical β-lactams antibiotic, 2.0 g bid) and Ornidazole (0.5 g bid) to prevent infection, and support treatment with hemostasis and rehydration within 2 weeks. Postoperative recovery was good and there has been no recurrence on the last follow-up before the present study was submitted.

Discussion

Castleman's disease (CD) (4) may be histologically divided into hyaline vascular (HV), plasma cell (PC) and mixed variants. The HV variant (5), which is composed of follicles and follicular lymph tissue, is commonly found in women aged 30–40 years and accounts for 90% of diagnosed cases. Phenotypically, this variant is defined by the presence of abundant hyperplastic hyaline capillaries between follicles and lymph sinuses. Furthermore, small lymphocytes in the mantle zone are arranged in concentric rings around the germinal center. The prognosis of the HV variant is mostly favorable following surgical resection. The PC variant (6) is a systemic disease that is more common among patients aged 50–60 years, and accounts for ~10% of diagnosed cases. This variant is defined by enlargement of follicular cells and an abundance of mature plasma cells, but a lower degree of angiogenesis. Treatment is administered systemically using hormone or immunosuppressive agents, but the prognosis of the PC variant is poor. Two clinical subtypes are classified as unicentric CD (UCD) and multicentric CD (MCD) (79). UCD occurs most frequently as a focal lesion of the HV variant that is not associated with obvious clinical symptoms and is often incidentally found during routine physical examination. MCD is a systemic disease, with the majority of the cases being of the PC variant, accompanied by systemic symptoms including fatigue, fever, night sweats, weight loss, joint pain and hepatosplenomegaly.

The imaging findings of UCD (10) often present as a single, well-defined soft tissue lesion, with rare cystic degeneration and focal necrosis. This finding may be associated with substantial angiogenesis and development of an extensive collateral circulation, so the lymph follicle tissue is not prone to necrosis (11). Non-enhanced CT images revealed homogeneous mild hypoattenuation within the lesion. Non-enhanced MR T1WI revealed a slightly hyperintensity compared with muscle. Furthermore, T2WI and DWI displayed high signals, suggesting diffusion restriction and supporting abundant cell proliferation (12). Contrast-enhanced CT/MRI of CD lesions often displays mild to moderate enhancement during the arterial phase, and persistent enhancement during the venous phase (13). This finding may be associated with the small arterial lumen and the subsequent reduction in blood velocity. Polymorphic calcification is commonly found in the lesions (14), which may be attributed to capillary proliferation with wall thickening and accompanied by glassy degeneration, fibrotic degeneration and the formation of calcareous deposits along the vessel wall. Imaging findings in MCD (15) include multiple enlarged lymph nodes with homogeneous density and mild to moderate enhancement on a contrast-enhanced scan, which pathologically reflects enlarged follicles and follicular plasma cell infiltration. In MCD is of the HV variant, the degree of enhancement is similar to that of UCD.

The reported imaging findings of hepatic CD (1623) (Table I) are commonly consistent with UCD. These findings and the calcification of the lesion may be helpful for radiological diagnosis of CD in the liver. Moreover, we observed that the signal, density, and pathological components of the strip-like area were consistent with those of the nodule. To the best of our knowledge, this finding has not been previously reported in the literature on hepatic CD to date. We hypothesized that the strip-like area may be attributed to lymphoid tissue, and lymphoproliferative disease may develop anywhere where lymphoid tissue is present (20). This strip-like area extending from the nodule may help with the differential diagnosis of hepatic CD from other diseases. However, pathological examination is required for a definitive diagnosis.

Table I.

Imaging characteristics of hepatic Castleman's disease.

Table I.

Imaging characteristics of hepatic Castleman's disease.

Imaging characteristics

AuthorsSex/age (years)SymptomsSize (cm)MarginsUltrasoundCT/MRIPathology(Refs.)
Rahmouni et alFemale/48Abdominal pain5Well-definedHypoechoicHypervascular, calcificationsHV(16)
Male/28Asymptomatic3LobulatedHypoechoicHypervascularHV
Cirillo et alFemale/43Abdominal pain13Well-definedNANonvascular, calcificationsHV(17)
Uzunlar et alFemale/56Vague abdominal pain3.5Well-definedHypoechoicHypervascularHV(18)
Karami et alFemale/5Abdominal pain3.7LobulatedSolid massHypervascularHV(19)
Jang et alFemale/40Abdominal pain, fever and chills2.2Well-definedNAHypervascularHV(20)
Miyoshi et alFemale/70Asymptomatic1.5Well-demarcatedHypoechoicHypovascularHV(21)
Dong et alFemale/57Asymptomatic3.3Well-definedNAHypervascular, diffusion restrictedHV(22)
Maundura et alFemale/64Asymptomatic1.4Well-definedHypoechoicHypervascular, diffusion restrictedHV(23)

[i] HV, hyaline-vascular; NA, not available; CT, computed tomography; MRI, magnetic resonance imaging.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

Authors' contributions

All authors contributed to this paper and approved the final version. LK wrote the case report. ZCL offered the assistance for the pathologic diagnosis of this case. XMS and LK revised and edited the final version.

Consent for publication

The patient and/or her family consented to the publication of the case details and associated images.

References

1 

Castleman B and Towne VW: Case records of the massachusetts general hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med. 251:396–400. 1954.PubMed/NCBI

2 

Talat N, Belgaumkar AP and Schulte KM: Surgery in Castleman's disease: A systematic review of 404 published cases. Ann Surg. 255:677–684. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Malayeri AA, El Khouli RH, Zaheer A, Jacobs MA, Corona-Villalobos CP, Kamel IR and Macura KJ: Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics. 31:1773–1791. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Soumerai JD, Sohani AR and Abramson JS: Diagnosis and management of Castleman disease. Cancer Control. 21:266–278. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Keller AR, Hochholzer L and Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 29:670–683. 1972. View Article : Google Scholar : PubMed/NCBI

6 

Ferry JA and Harris NL: Atlas of lymphoid hyperplasia and lymphoma. WB. Saunders Company; pp. 1–1042. 1997

7 

Gaba AR, Stein RS, Sweet DL and Variakojis D: Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 69:86–90. 1978. View Article : Google Scholar : PubMed/NCBI

8 

Casper C: The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care. Br J Haematol. 129:3–17. 2005. View Article : Google Scholar : PubMed/NCBI

9 

van Rhee F, Stone K, Szmania S, Barlogie B and Singh Z: Castleman disease in the 21st century: An update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 8:486–498. 2010.PubMed/NCBI

10 

Zhou LP, Zhang B, Peng WJ, Yang WT, Guan YB and Zhou KR: Imaging findings of Castleman disease of the abdomen and pelvis. Abdom Imaging. 33:482–488. 2008. View Article : Google Scholar : PubMed/NCBI

11 

McAdams HP, Rosado-de-Christenson M, Fishback NF and Templeton PA: Castleman disease of the thorax: Radiologic features with clinical and histopathologic correlation. Radiology. 209:221–228. 1998. View Article : Google Scholar : PubMed/NCBI

12 

White NS, McDonald C, Farid N, Kuperman J, Karow D, Schenker-Ahmed NM, Bartsch H, Rakow-Penner R, Holland D, Shabaik A, et al: Diffusion-weighted imaging in cancer: Physical foundation and application of restriction spectrum imaging. Cancer Res. 74:4638–4652. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Jiang XH, Song HM, Liu QY, Cao Y, Li GH and Zhang WD: Castleman disease of the neck: CT and MR imaging findings. Eur J Radiol. 83:2041–2050. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Bonekamp D, Horton KM, Hruban RH and Fishman EK: Castleman disease: The great mimic. Radiographics. 31:1793–1807. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Johkoh T, Müller NL, Ichikado K, Nishimoto N, Yoshizaki K, Honda O, Tomiyama N, Naitoh H, Nakamura H and Yamamoto S: Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology. 209:477–481. 1998. View Article : Google Scholar : PubMed/NCBI

16 

Rahmouni A, Golli M, Mathieu D, Anglade MC, Charlotte F and Vasile N: Castleman disease mimicking liver tumor: CT and MR features. J Comput Assist Tomogr. 16:699–703. 1992. View Article : Google Scholar : PubMed/NCBI

17 

Cirillo RL Jr, Vitellas KM, Deyoung BR and Bennett WF: Castleman disease mimicking a hepatic neoplasm. Clin Imaging. 22:124–129. 1998. View Article : Google Scholar : PubMed/NCBI

18 

Uzunlar AK, Ozateş M, Yaldiz M, Büyükbayram H and Ozaydin M: Castleman's disease in the porta hepatis. Eur Radiol. 10:1913–1915. 2000. View Article : Google Scholar : PubMed/NCBI

19 

Karami H, Sahebpour AA, Ghasemi M, Karami H, Dabirian M, Vahidshahi K, Masiha F and Shahmohammadi S: Hyaline vascular-type Castleman's disease in the hilum of liver: A case report. Cases J. 3:742010. View Article : Google Scholar : PubMed/NCBI

20 

Jang SY, Kim BH, Kim JH, Ha SH, Hwang JA, Yeon JW, Kim KH and Paik SY: A case of Castleman's disease mimicking a hepatocellular carcinoma: A case report and review of literature. Korean J Gastroenterol. 59:53–57. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Miyoshi H, Mimura S, Nomura T, Tani J, Morishita A, Kobara H, Mori H, Yoneyama H, Deguchi A, Himoto T, et al: A rare case of hyaline-type Castleman disease in the liver. World J Hepatol. 5:404–408. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Dong A, Dong H and Zuo C: Castleman disease of the porta hepatis mimicking exophytic hepatocellular carcinoma on CT, MRI, and FDG PET/CT. Clin Nucl Med. 39:e69–e72. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Maundura M, Hayward G, McKee C and Koea JB: Primary Castleman's disease of the liver. J Gastrointest Surg. 21:417–419. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April-2018
Volume 8 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pohlodek K, Jáni P and Mečiarová I: Granular cell tumor in axillary region: A rare entity. Mol Clin Oncol 8: 579-581, 2018
APA
Pohlodek, K., Jáni, P., & Mečiarová, I. (2018). Granular cell tumor in axillary region: A rare entity. Molecular and Clinical Oncology, 8, 579-581. https://doi.org/10.3892/mco.2018.1568
MLA
Pohlodek, K., Jáni, P., Mečiarová, I."Granular cell tumor in axillary region: A rare entity". Molecular and Clinical Oncology 8.4 (2018): 579-581.
Chicago
Pohlodek, K., Jáni, P., Mečiarová, I."Granular cell tumor in axillary region: A rare entity". Molecular and Clinical Oncology 8, no. 4 (2018): 579-581. https://doi.org/10.3892/mco.2018.1568